A pilot study of 68 Ga-PSMA-617 PET/CT imaging and 177Lu-EB-PSMA-617 radioligand therapy in patients with adenoid cystic carcinoma
Abstract Background This pilot study was designed to evaluate the diagnostic value of 68 Ga-PSMA-617 and 18F-FDG PET/CT in adenoid cystic carcinoma (ACC) and to assess the safety and therapeutic response to PSMA radioligand therapy (RLT) in ACC patients. Methods Thirty patients pathologically diagno...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2022-08-01
|
| Series: | EJNMMI Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13550-022-00922-x |
| _version_ | 1798038775749672960 |
|---|---|
| author | Guochang Wang Mengjiao Zhou Jie Zang Yuanyuan Jiang Xiaohong Chen Zhaohui Zhu Xiaoyuan Chen |
| author_facet | Guochang Wang Mengjiao Zhou Jie Zang Yuanyuan Jiang Xiaohong Chen Zhaohui Zhu Xiaoyuan Chen |
| author_sort | Guochang Wang |
| collection | DOAJ |
| description | Abstract Background This pilot study was designed to evaluate the diagnostic value of 68 Ga-PSMA-617 and 18F-FDG PET/CT in adenoid cystic carcinoma (ACC) and to assess the safety and therapeutic response to PSMA radioligand therapy (RLT) in ACC patients. Methods Thirty patients pathologically diagnosed with ACC were recruited into the cohort. Each patient underwent 68 Ga-PSMA-617 and 18F-FDG PET/CT within 1 week. The number and SUVmax of PET-positive lesions were recorded and compared. Four patients accepted RLT using 177Lu-EB-PSMA-617, in a dosage of approximately 1.85 GBq (50 mCi) per cycle for up to 3 cycles. Results Compared with 18F-FDG, 68 Ga-PSMA-617 revealed more PET-positive extrapulmonary tumors (157 vs. 141, P = 0.016) and higher SUVmax (8.8 ± 3.6 vs. 6.4 ± 4.2, P = 0.027). However, 68 Ga-PSMA-617 revealed less PET-positive pulmonary lesions (202 vs. 301, P < 0.001) and lower SUVmax of tumors (3.1 ± 3.0 vs. 4.2 ± 3.9, P < 0.001) than 18F-FDG. The combination of 68 Ga-PSMA-617 and 18F-FDG can detect 469 PET-positive lesions, which was superior to each alone (469 vs. 359 vs. 442, P < 0.001). Two patients achieved remarkable response after PSMA RLT, while the other two patients showed reduced tumor uptake of recurrent foci, lung and liver metastases, whereas increased SUVmax of bone metastases. Conclusions 68 Ga-PSMA-617 PET/CT is a valuable imaging modality for the detection of ACC and combining with 18F-FDG PET/CT will achieve a higher detection efficiency. PSMA RLT may be a promising treatment for ACC and is worth of further investigation. Trial registration: Diagnosis of Adenoid Cystic Carcinoma on 68 Ga-PSMA-617 PET-CT and Therapy With 177Lu-EB-PSMA-617 (NCT04801264, Registered 16 March 2021, retrospectively registered). URL of registry: https://clinicaltrials.gov/ct2/show/NCT04801264 . |
| first_indexed | 2024-04-11T21:44:58Z |
| format | Article |
| id | doaj.art-79f762aff3a2468a991bdc3ee8e06bff |
| institution | Directory Open Access Journal |
| issn | 2191-219X |
| language | English |
| last_indexed | 2024-04-11T21:44:58Z |
| publishDate | 2022-08-01 |
| publisher | SpringerOpen |
| record_format | Article |
| series | EJNMMI Research |
| spelling | doaj.art-79f762aff3a2468a991bdc3ee8e06bff2022-12-22T04:01:26ZengSpringerOpenEJNMMI Research2191-219X2022-08-0112111310.1186/s13550-022-00922-xA pilot study of 68 Ga-PSMA-617 PET/CT imaging and 177Lu-EB-PSMA-617 radioligand therapy in patients with adenoid cystic carcinomaGuochang Wang0Mengjiao Zhou1Jie Zang2Yuanyuan Jiang3Xiaohong Chen4Zhaohui Zhu5Xiaoyuan Chen6Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical CollegeDepartment of Otolaryngology Head and Neck Surgery, Key Laboratory of Otolaryngology Head and Neck Surgery, Ministry of Education, Beijing Institute of Otolaryngology, Beijing Tongren Hospital, Capital Medical UniversityDepartment of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical CollegeDepartment of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical CollegeDepartment of Otolaryngology Head and Neck Surgery, Key Laboratory of Otolaryngology Head and Neck Surgery, Ministry of Education, Beijing Institute of Otolaryngology, Beijing Tongren Hospital, Capital Medical UniversityDepartment of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical CollegeDepartments of Diagnostic Radiology, Surgery, Chemical and Biomolecular Engineering, and Biomedical Engineering, Yong Loo Lin School of Medicine and Faculty of Engineering, National University of SingaporeAbstract Background This pilot study was designed to evaluate the diagnostic value of 68 Ga-PSMA-617 and 18F-FDG PET/CT in adenoid cystic carcinoma (ACC) and to assess the safety and therapeutic response to PSMA radioligand therapy (RLT) in ACC patients. Methods Thirty patients pathologically diagnosed with ACC were recruited into the cohort. Each patient underwent 68 Ga-PSMA-617 and 18F-FDG PET/CT within 1 week. The number and SUVmax of PET-positive lesions were recorded and compared. Four patients accepted RLT using 177Lu-EB-PSMA-617, in a dosage of approximately 1.85 GBq (50 mCi) per cycle for up to 3 cycles. Results Compared with 18F-FDG, 68 Ga-PSMA-617 revealed more PET-positive extrapulmonary tumors (157 vs. 141, P = 0.016) and higher SUVmax (8.8 ± 3.6 vs. 6.4 ± 4.2, P = 0.027). However, 68 Ga-PSMA-617 revealed less PET-positive pulmonary lesions (202 vs. 301, P < 0.001) and lower SUVmax of tumors (3.1 ± 3.0 vs. 4.2 ± 3.9, P < 0.001) than 18F-FDG. The combination of 68 Ga-PSMA-617 and 18F-FDG can detect 469 PET-positive lesions, which was superior to each alone (469 vs. 359 vs. 442, P < 0.001). Two patients achieved remarkable response after PSMA RLT, while the other two patients showed reduced tumor uptake of recurrent foci, lung and liver metastases, whereas increased SUVmax of bone metastases. Conclusions 68 Ga-PSMA-617 PET/CT is a valuable imaging modality for the detection of ACC and combining with 18F-FDG PET/CT will achieve a higher detection efficiency. PSMA RLT may be a promising treatment for ACC and is worth of further investigation. Trial registration: Diagnosis of Adenoid Cystic Carcinoma on 68 Ga-PSMA-617 PET-CT and Therapy With 177Lu-EB-PSMA-617 (NCT04801264, Registered 16 March 2021, retrospectively registered). URL of registry: https://clinicaltrials.gov/ct2/show/NCT04801264 .https://doi.org/10.1186/s13550-022-00922-x68 Ga-PSMA-617 PET/CT18F-FDG PET/CTAdenoid cystic carcinoma177Lu-EB-PSMA-617 |
| spellingShingle | Guochang Wang Mengjiao Zhou Jie Zang Yuanyuan Jiang Xiaohong Chen Zhaohui Zhu Xiaoyuan Chen A pilot study of 68 Ga-PSMA-617 PET/CT imaging and 177Lu-EB-PSMA-617 radioligand therapy in patients with adenoid cystic carcinoma EJNMMI Research 68 Ga-PSMA-617 PET/CT 18F-FDG PET/CT Adenoid cystic carcinoma 177Lu-EB-PSMA-617 |
| title | A pilot study of 68 Ga-PSMA-617 PET/CT imaging and 177Lu-EB-PSMA-617 radioligand therapy in patients with adenoid cystic carcinoma |
| title_full | A pilot study of 68 Ga-PSMA-617 PET/CT imaging and 177Lu-EB-PSMA-617 radioligand therapy in patients with adenoid cystic carcinoma |
| title_fullStr | A pilot study of 68 Ga-PSMA-617 PET/CT imaging and 177Lu-EB-PSMA-617 radioligand therapy in patients with adenoid cystic carcinoma |
| title_full_unstemmed | A pilot study of 68 Ga-PSMA-617 PET/CT imaging and 177Lu-EB-PSMA-617 radioligand therapy in patients with adenoid cystic carcinoma |
| title_short | A pilot study of 68 Ga-PSMA-617 PET/CT imaging and 177Lu-EB-PSMA-617 radioligand therapy in patients with adenoid cystic carcinoma |
| title_sort | pilot study of 68 ga psma 617 pet ct imaging and 177lu eb psma 617 radioligand therapy in patients with adenoid cystic carcinoma |
| topic | 68 Ga-PSMA-617 PET/CT 18F-FDG PET/CT Adenoid cystic carcinoma 177Lu-EB-PSMA-617 |
| url | https://doi.org/10.1186/s13550-022-00922-x |
| work_keys_str_mv | AT guochangwang apilotstudyof68gapsma617petctimagingand177luebpsma617radioligandtherapyinpatientswithadenoidcysticcarcinoma AT mengjiaozhou apilotstudyof68gapsma617petctimagingand177luebpsma617radioligandtherapyinpatientswithadenoidcysticcarcinoma AT jiezang apilotstudyof68gapsma617petctimagingand177luebpsma617radioligandtherapyinpatientswithadenoidcysticcarcinoma AT yuanyuanjiang apilotstudyof68gapsma617petctimagingand177luebpsma617radioligandtherapyinpatientswithadenoidcysticcarcinoma AT xiaohongchen apilotstudyof68gapsma617petctimagingand177luebpsma617radioligandtherapyinpatientswithadenoidcysticcarcinoma AT zhaohuizhu apilotstudyof68gapsma617petctimagingand177luebpsma617radioligandtherapyinpatientswithadenoidcysticcarcinoma AT xiaoyuanchen apilotstudyof68gapsma617petctimagingand177luebpsma617radioligandtherapyinpatientswithadenoidcysticcarcinoma AT guochangwang pilotstudyof68gapsma617petctimagingand177luebpsma617radioligandtherapyinpatientswithadenoidcysticcarcinoma AT mengjiaozhou pilotstudyof68gapsma617petctimagingand177luebpsma617radioligandtherapyinpatientswithadenoidcysticcarcinoma AT jiezang pilotstudyof68gapsma617petctimagingand177luebpsma617radioligandtherapyinpatientswithadenoidcysticcarcinoma AT yuanyuanjiang pilotstudyof68gapsma617petctimagingand177luebpsma617radioligandtherapyinpatientswithadenoidcysticcarcinoma AT xiaohongchen pilotstudyof68gapsma617petctimagingand177luebpsma617radioligandtherapyinpatientswithadenoidcysticcarcinoma AT zhaohuizhu pilotstudyof68gapsma617petctimagingand177luebpsma617radioligandtherapyinpatientswithadenoidcysticcarcinoma AT xiaoyuanchen pilotstudyof68gapsma617petctimagingand177luebpsma617radioligandtherapyinpatientswithadenoidcysticcarcinoma |